New anti-corona pill shows high efficacy! Is this the game changer? Hospitals should be relieved
After the U.S. pharmaceutical company Pfizer had already reported weeks ago from a drug against the coronavirus, it is now in studies have shown that the anti-corona pill is actually a high effectiveness against the insidious coronavirus.
Studies show effectiveness of Pfizer drug against coronavirus
For some time, the U.S. pharmaceutical giant Pfizer is pushing the development of an an drug against the coronavirus. Now the data clinical trial of the corona drug Paxlovid is available. Apparently, the pill is highly effective against the disease. In high-risk patients, the risk of hospitalization or death from Covid-19 is said to be reduced by 89 percent. The company gave these figures on Monday. However, it said a prerequisite for this is that drug treatment is started within 3 days of the onset of symptoms. If started 5 days after the first symptoms, the protection is then 88 percent. In early November, 2,246 adult volunteers had participated in this study.
Medicine should have high efficacy against Omikron variant
In view of the increased occurrence of the Omikron variant, Pfizer had already tested the drug in in vitro studies on the novel variant. It had emerged that the drug was also likely to be effective against the Omikron variant of the coronavirus. Pfizer CEO Albert Bourla confirmed that the drug “is saving the lives of patients around the world.” Since it appears to work against different variants of the coronavirus, the drug could become another effective tool against the coronavirus. Pfizer’s drug is taken orally and does not have to be administered in a hospital setting.
The pill is designed to prevent the viruses from replicating in the cells of the human body once ingested. In the treatment, paxlovide is to be combined with the drug ritonavir, which is also currently used to treat HIV patients.
Clinical Trials Complete – Approval Imminent for Covid Drug
This means that the clinical trials for paxlovide are now complete. The pharmaceutical company has since filed for emergency approval with the U.S. Food and Drug Administration. In addition, Paxlovid is also already under review by the European Medicines Agency (EMA). In mid-November, the European Medicines Agency (EMA) announced that it had already begun reviewing paxlovid. Apparently, the decision of the EMA on the approval of the drug should be made very soon. Only a few weeks ago, the US pharmaceutical company Merck Sharp & Dohme (MSD) was the first pharmaceutical company to develop a drug against the coronavirus, the drug Molnupiravir. However, the protection against severe courses there is reportedly only 30 percent.